The World Is Demanding New Options for Male Birth Control.
We’re gathering the world’s most accomplished minds in contraception to develop a new male contraceptive method we’ve named Plan A™.
A GLOBAL NEED FOR MORE FAMILY PLANNING OPTIONS
The current options for contraception and family planning focus mostly on female fertility, burdening women with a majority of the responsibility for reproductive planning. Negative side effects and health risks associated with these options have also led to many women in the U.S. discontinuing their use.
Male birth control options have traditionally been limited to vasectomy, condoms, and withdrawal. The development of a non-hormonal, long-lasting, and reversible male birth control option would offer a greater choice of control for both individuals and couples when planning their future.
The mission of NEXT Life Sciences is to design and develop such a male birth control option, which we’ve named Plan A™.
50%
Of pregnancies worldwide are unintended.
25%
Of women experience life-altering side effects from their birth control options.
19M
U.S. men are interested in new male contraceptive methods.
17M
U.S. men are actively looking for a new contraceptive option that fits their lifestyle and relationship.
RECENT NEWS
Charlie Sabgir from the Young Men Research Project speaks with with Founder of Plan A™, L.R. Fox, about the past, present, and future of male birth control options.
Long limited to condoms and vasectomy, male contraception could soon have new options. Several methods are advancing in clinical trials, paving the way for more balanced sharing of responsibility between men and women.
Plan A™ by NEXT Life Sciences offers a reversible, non-hormonal male contraceptive using Vasalgel®. Men, couples, and physicians are embracing it as a solution to a long-unmet need.
Advancing Plan A™ alongside NLS-133, NEXT Life Sciences is responding directly to a long-unmet need, expanding contraceptive choice for men and couples worldwide.
Currently, the only widely used forms of contraception available to men are condoms and vasectomies. There’s a substantial potential market for other methods.
Newly issued patent covers a new medical device and method to deliver and remove hydrogel within the body, including Plan A™’s sperm occlusion system.
NEXT Life Sciences has been part of the StartUp Health community since 2022, advancing work that cuts across multiple Health Moonshots, from Men’s Health and Women’s Health to Access to Care. As Dr. Walley puts it, “The world is ready for a modern, non-hormonal, fully reversible male contraceptive.” The next chapters in this story may change reproductive health forever.
Investment in medical/health issues is a long-term proposition. We talk to those making a health treatment focused on male contraception.
Peter Barton Hutt, former Chief Counsel at the FDA and pioneer of medical device regulatory policy, joins as Plan A™ concludes successful clinical trials.
We spoke to Darlene Walley, CEO of Next Life Sciences, about Plan A, the need it is addressing, and why she expects men and women to see it as a welcome alternative to current choices.
As a leader in this emerging field, I often get announcements of breakthrough technologies. A recent email grabbed my attention: “Male Contraceptive Plan A Completes First North American Clinical Trial with 100% Success.”
Physicians from Canada and Australia have tested the Plan A™ male birth control delivery system with 100% success in 50 men.
In this groundbreaking interview, Dr. Darlene Walley—biotech leader and CEO of NEXT Life Sciences—shares the bold vision behind Plan A™, the world’s first long-lasting, non-hormonal, and reversible male contraceptive in development.
NEXT Life Sciences is raising $20 million to develop male contraceptive product Plan A, CEO Darlene Walley tells Axios exclusively.
For over six decades, birth control has largely been considered a woman’s responsibility, while men have had only two choices: condoms or vasectomy. But that’s about to change…
Following a thorough review of the company’s progress, MCI has unanimously approved a second year’s installment of $200,000
Fortune‘s Nina Ajemian reports on the state of male birth control—amid a tumultuous political environment for women’s health and drug approvals.
NEXT Life Sciences, a male contraceptive developer, appointed Darlene Walley as CEO of Plan A
Peter Barton Hutt: Former FDA Chief Counsel joins the Advisory Board of NEXT Life Sciences
Trends over the last two years back up these observations, all pointing toward one conclusion: It’s high time that we develop new birth control solutions for men.
Tips on how to integrate a solution into an often-resistant healthcare system, featuring L.R. Fox, founder of NEXT Life Sciences.
How Plan A is changing the game when it comes to reversible, set-it-and-forget-it male contraceptives.
The future of male contraceptives and how knowing more about birth control makes you a better partner.
Trials of a revolutionary ‘switch-on/off’ contraceptive could begin in the UK, Australia, and New Zealand as early as next year and the company is looking for men aged 25-65 to take part.
THE WORLD IS READY FOR SOMETHING NEW
Join our newsletter for exciting milestone updates from NEXT Life Sciences and for information about joining our clinical trials as they begin.
United Nations Population Fund. State of World Population Report.
Drugwatch. Survey.
Male Contraceptive Initiative. Annual Report.